Behavioral effects of family-selective inhibitors of cyclic nucleotide phosphodiesterases

Pharmacology Biochemistry and Behavior

Volumn 63, Issue 1, 1999, Pages 185-192

  O'Donnell, James M ^a   Frith, Sandra ^a  

^a LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

Adenylyl cyclase; Antidepressant drugs; Behavior; Desipramine; Milrinone; Phosphodiesterase; Rolipram; Trequinsin; Vinpocetine; Zaprinast

Indexed keywords

CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; DESIPRAMINE; MILRINONE; PHOSPHODIESTERASE INHIBITOR; ROLIPRAM; TREQUINSIN; TRICYCLIC ANTIDEPRESSANT AGENT; VINPOCETINE; ZAPRINAST;

ARTICLE; BEHAVIOR; DOSE RESPONSE; PRIORITY JOURNAL; REINFORCEMENT;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; 3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANIMALS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CONDITIONING, OPERANT; DESIPRAMINE; ISOQUINOLINES; MALE; MILRINONE; PHOSPHODIESTERASE INHIBITORS; PURINONES; PYRROLIDINONES; RATS; RATS, SPRAGUE-DAWLEY; REINFORCEMENT SCHEDULE; ROLIPRAM; TETRAHYDROISOQUINOLINES; VINCA ALKALOIDS;

EID: 0033003946     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(98)00267-6     Document Type: Article

References (58)

1. Beavo J.A., Conti M., Heaslip R.J. Multiple cyclic nucleotide phosphodiesterases. Mol. Pharmacol. 46:1994;399-405.
2. Becker A., Grecksch G. Nootropic drugs have different effects on kindling-induced learning deficits in rats. Pharmacol. Res. 32:1995;115-122.
3. Bolger G.B. Molecular biology of the cyclic AMP-specific nucleotide phosphodiesterases. A diverse family of regulatory enzymes Cell. Signal. 6:1994;851-859.
4. Challiss R.A., Nicholson C.D. Effects of selective phosphodiesterase inhibition on cyclic AMP hydrolysis in rat cerebral cortical slices. Br. J. Pharmacol. 99:1990;47-52.
5. Dews P.B. A behavioral output enhancing effect of imipramine in pigeons. Int. J. Neuropharmacol. 1:1962;265-272.
6. Dundore R.L., Clas D.M., Wheeler L.T., Habeeb P.G., Bode D.C., Buchholz R.A., Silver P.J., Pagani E.D. Zaprinast increases the cyclic GMP levels in plasma and aortic tissue of rats. Eur. J. Pharmacol. 249:1993;293-297.
7. Eckmann F., Fichte K., Meya U., Sastre-y-Hernandez M. Rolipram in major depression. Results of a double-blind comparative study with amitriptyline Curr. Ther. Res. 43:1988;291-295.
8. Engels P., Fichtel K., Lubbert H. Expression and regulation of human and rat phosphodiesterase type IV isogenes. FEBS Lett. 350:1994;291-295.
9. Fleischhacker W.W., Hinterhuber H., Bauer H., Pflug B., Berner P., Simhandl C., Gerlach W., Jaklitsch H.et al. A multicenter double-blind study of three different doses of the new cAMP-phosphodiesterase inhibitor rolipram in patients with major depressive disorder. Neuropsychobiology. 26:1992;59-64.
10. Frazer A., Conway P.G. Pharmacologic mechanisms of action of antidepressants. Psychiatr. Clin. North Am. 7:1984;575-586.
11. Griebel G., Misslin R., Vogel E., Bourguignon J. Behavioral effects of rolipram and structurally related compounds in mice. Behavioral sedation of cAMP phosphodiesterase inhibitors Pharmacol. Biochem. Behav. 39:1991;321-323.
12. Haraguchi H., Kuribara H. Behavioral effects of adenosine agonists. Evaluation by punishment, discrete shuttle avoidance and activity tests in mice J. Pharmacol. 55:1991;303-310.
13. Horowski R., Sastre-y-Hernandez M. Clinical effects of the neurotropic selective cAMP phosphodiesterase inhibitor rolipram in depressed patients. Global evaluation of the preliminary reports Curr. Ther. Res. 38:1985;23-29.
14. Houslay M.D. Compartmentalization of cyclic AMP phosphodiesterases, signaling crosstalk, desensitization, and the phosphorylation of Gi-2 add cell specific personalization to the control of the levels of the second messenger cyclic AMP. Adv. Enzyme Regul. 35:1995;303-338.
15. Howell L.L. Comparative effects of caffeine and selective phosphodiesterase inhibitors on respiration and behavior in rhesus monkeys. J. Pharmacol. Exp. Ther. 266:1993;894-903.
16. Kehne J.H., Boulis N.M., Davis M. Effects of the phosphodiesterase inhibitor rolipram on the acoustic startle response in rats. Psychopharmacology (Berlin). 105:1991;27-36.
17. Lal B., Dohadwalla A.N., Dadkar N.K., D'Sa A., de Souza N.J. Trequinsin, a potent new antihypertensive vasodilator in the series of 2-(arylimino)-3-alkyl-9, 10-dimethoxy 3, 4, 6, 7-tetrahydro-2H-pyrimido [6, 1-a]isoquinolin-4-ones. J. Med. Chem. 27:1984;1470-1480.
18. Loughney K., Ferguson K. Identification and quantification of PDE isoenzymes and subtypes by molecular biological methods. Schudt C., Dent G., Rabe K.F. Phosphodiesterase inhibitors. 1996;1-19 Academic Press, San Diego.
19. Mizokawa T., Kimura K., Ikoma Y., Hara K., Oshino N., Yamamoto T., Ueki S. The effect of a selective phosphodiesterase inhibitor, rolipram, on muricide in olfactory bulbectomized rats. Jpn: J. Pharmacol. 48:1988;357-364.
20. Mochizuki N., Uchida S., Miyata H. Cardiovascular effects of NSP-804 and NSP-805, novel cardiotonic agents with vasodilator properties. J. Cardiovasc. Pharmacol. 21:1993;983-995.
21. Nicholson C.D., Jackman S.A., Wilke R. The ability of denbufylline to inhibit cyclic nucleotide phosphodiesterase and its affinity for adenosine receptors and the adenosine re-uptake site. Br. J. Pharmacol. 97:1989;889-897.
22. Nicholson D., Reid A., Sawynok J. Effects of forskolin and phosphodiesterase inhibitors on spinal antinociception by morphine. Pharmacol. Biochem. Behav. 38:1991;753-758.
23. O'Donnell J.M. Behavioral effects of beta adrenergic agonists and antidepressant drugs after down-regulation of beta-2 adrenergic receptors by clenbuterol. J. Pharmacol. Exp. Ther. 254:1990;147-157.
24. O'Donnell J.M. Antidepressant-like effects of rolipram and other inhibitors of cyclic AMP phosphodiesterase on behavior maintained by differential reinforcement of low response rate. J. Pharmacol. Exp. Ther. 264:1993;1168-1178.
25. O'Donnell J.M. Pharmacological characterization of the discriminative stimulus effects of clenbuterol. Pharmacol. Biochem. Behav. 58:1997;813-818.
26. O'Donnell J.M., Frith S., Wilkins J. Involvement of beta-1 and beta-2 adrenergic receptors in antidepressant-like effects of centrally administered isoproterenol. J. Pharmacol. Exp. Ther. 271:1994;246-254.
27. O'Donnell J.M., Seiden L.S. Differential-reinforcement-of-low-response-rate 72-second schedule. Selective effects of antidepressant drugs J. Pharmacol. Exp. Ther. 224:1983;80-88.
28. Okuyama S., Hashimoto-Kitsukawa S., Ogawa S., Imagawa Y., Kawashima K., Kawashima Y., Araki H., Otomo S. Effects of VA-045, a novel apovincaminic acid derivative, on age-related impairment evidence in electroencephalograph, caudate spindle, a passive avoidance task and cerebral blood flow in rats. Gen. Pharmacol. 25:1994;1311-1320.
29. 125I-iodopindolol to beta-1 adrenoceptors in the amygdala of rat after antidepressant treatments. J. Pharmacol. Exp. Ther. 257:1991;681-690.
30. Ortmann R., Meisburger J.G. Rolipram forms a potent discriminative stimulus in drug discrimination experiments in rats. Psychopharmacology (Berlin). 89:1986;273-277.
31. Overstreet D.H., Schiller G.D., Double K. Antidepressant effects of rolipram in a genetic animal model of depression. Pharmacol. Biochem. Behav. 34:1989;691-696.
32. Phillis J.W., Wu P.H. The effect of various centally active drugs on adenosine uptake by the central nervous system. Comp. Biochem. Physiol. 72C:1982;179-187.
33. Randt C.T., Judge M.E., Bonnet K.A., Quartermain D. Brain cyclic AMP and memory in mice. Pharmacol. Biochem. Behav. 17:1982;677-680.
34. Saccomano N.A., Vinick F.J., Koe B.K., Nielsen J.A., Whalen W.M., Meltz M., Phillips D., Thadieo P.F., Jung S., Chapin D.S., Lebel L.A., Russo L.L., Helweg D.A., Johnson J.L., Ives J.L., Williams I.H. Calcium-independent phosphodiesterase inhibitors as putative antidepressants. J. Med. Chem. 34:1991;291-298.
35. Schmiechen R., Schneider H.H., Wachtel H. Close correlation between behavioural response and binding in vivo for inhibitors of the rolipram-sensitive phosphodiesterase. Psychopharmacology (Berlin). 102:1990;17-20.
36. Schneider H.H., Yamaguchi M., Andrews J.S., Stephens D.N. Discriminative stimulus properties of the stereoisomers of the phosphodiesterase inhibitor rolipram. Pharmacol. Biochem. Behav. 50:1995;211-217.
37. Schudt C., Dent G., Rabe K.F. Phosphodiesterase inhibitors. 1996;Academic Press, San Diego.
38. Scott A.I.F., Perini A.F., Shering P.A., Whalley L.J. In-patient major depression. Is rolipram as effective as amitriptyline? Eur. J. Clin. Pharmacol. 40:1991;127-129.
39. Seiden L.S., Dykstra L.A. Psychopharmacology. A biochemical and behavioral approach:1977;Van Nostrand Reinhold, New York.
40. Seiden, L. S.; O'Donnell, J. M.: Effects of antidepressant drugs on DRL behavior. In: Seiden, L. S.; Balster, R. L., eds. Behavioral Pharmacology: The current status. Neurology and Neurobiology, vol. 13. Alan R. Liss: New York; 1985: 323-338.
41. Sette C., Iona S., Conti M. The short-term activation of a rolipram-sensitive, cAMP specific phosphodiesterase by TSH in thyroid FRTL-5 cells is mediated by a cAMP-dependent phosphorylation. J. Biol. Chem. 269:1994;9245-9252.
42. Shakur Y., Wilson M., Pooley L., Lobban M., Griffiths S.L., Campbell A.M., Beattie J., Daly C., Houslay M.D. Identification and characterization of the type IVA cyclic AMP-specific phosphodiesterase RD1 as a membrane-bound protein expressed in cerebellum. Biochem. J. 306:1995;801809.
43. Smith C.B. Effects of d-amphetamine upon operant behavior of pigeons. Enhancement by reserpine J. Pharmacol. Exp. Ther. 146:1964;167-174.
44. Snapper A.G., Kadden R.M., Inglis G.B. State notation of behavioral procedures. Behav. Res. Methods Instrum. 14:1982;329-343.
45. Swinnen J.V., Joseph D.R., Conti M. Molecular cloning of rat homologues of the Drosophila melanogaster dunce cAMP phosphodiesterase. Evidence for a family of genes Proc. Natl. Acad. Sci. USA. 86:1989;5325-5329.
46. Thompson W.J. Cyclic nucleotide phosphodiesterases. Pharmacology, biochemistry, and function Pharmacol. Ther. 51:1991;13-33.
47. Torphy T.J., Zhou H., Cieslinski L.B. Stimulation of beta adrenoceptors in a human monocyte cell line (U937) up-regulates cyclic AMP-specific phosphodiesterase activity. J. Pharmacol. Exp. Ther. 263:1992;1195-1205.
48. Trapani A.J., Smits G.J., McGraw D.E., McMahon E.G., Blaine E.H. Hemodynamic basis for the depressor activity of zaprinast, a selective cyclic GMP phosphodiesterase inhibitor. J. Pharmacol. Exp. Ther. 258:1991;269-277.
49. Verghese M.W., McConnell R.T., Lenhard J.M., Hamacher L., Jin S.L. Regulation of distinct cyclic AMP-specific phosphodiesterase (phosphodiesterase type 4) isozymes in human monocytic cells. Mol. Pharmacol. 47:1995;1164-1171.
50. Villiger J.W., Dunn A.J. Phosphodiesterase inhibitors facilitate memory for passive avoidance conditioning. Behav. Neural Biol. 31:1981;354-359.
51. Wachtel H. Neurotropic effects of the optical isomers of the selective adenosine 3′, 5′-monophosphate phosphodiesterase inhibitor rolipram in rats in-vivo. J. Pharm. Pharmacol. 35:1983;440-444.
52. Wachtel H. Potential antidepressant activity of rolipram and other selective cyclic adenosine 3′, 5′-monophosphate phosphodiesterase inhibitors. Neuropharmacology. 22:1983;267-272.
53. Wachtel H. Defective second-messenger function in the etiology of endogenous depression. Novel therapeutic approaches Briley M., Fillion G. Concepts in depression. 1988;277-293 MacMillan Press, London.
54. Wachtel H., Schneider H.H. Rolipram, a novel antidepressant drug, reverses the hypothermia and hypokinesia of monoamine-depleted mice by an action beyond postsynaptic monoamine receptors. Neuropharmacology. 25:1986;1119-1126.
55. Winer B.J. Statistical principles in experimental design. 1971;McGraw Hill, New York.
56. Ye Y., O'Donnell J.M. Diminished noradrenergic activity in the brain down-regulates Type 4 phosphodiesterase in rat cerebral cortex. J. Neurochem. 66:1996;1894-1902.
57. Ye Y., Conti M., Houslay M.D., Farooqui S., Chen M., O'Donnell J.M. Noradrenergic activity differentially regulates the expression of rolipram-sensitive, high-affinity cyclic AMP phosphodiesterase (PDE4) in the rat brain. J. Neurochem. 69:1997;2397-2404.
58. Zeller E., Stief H.J., Pflug B., Sastre-y-Hernandez M. Results of a phase II study of the antidepressant effect of rolipram. Pharmacopsychiatry. 17:1984;188-190.